A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation

被引:36
作者
Kovarik, JM
Nashan, B
Neuhaus, P
Clavien, PA
Gerbeau, C
Hall, ML
Korn, A
机构
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Med Hsch Hannover, Hannover, Germany
[3] Free Univ Berlin, Klinikum Rudolf Virchow, D-1000 Berlin, Germany
[4] Duke Univ, Med Ctr, Durham, NC USA
关键词
D O I
10.1067/mcp.2001.114887
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Basiliximab is a high-affinity interleukin-2 receptor (CD25) chimeric monoclonal antibody used for immunoprophylaxis in organ transplantation. It was assessed in a randomized, double-blind, placebo-controlled efficacy trial in de novo liver allograft recipients who received 40 mg of basiliximab (20 mg on days 0 and 4) in addition to baseline immunosuppression with cyclosporine (INN, ciclosporin) microemulsion and corticosteroids. Methods: Serial blood samples (8.3 +/- 1.4 per patient) were collected during 12 weeks after transplantation from 184 basiliximab-treated patients, and empirical Bayes estimates of each patient's disposition parameters were derived. Demographic-clinical covariates were explored with regression methods. Results: Basiliximab clearance was 55 +/- 26 mL/h, the distribution volume was 9.7 +/- 4.2 L, and the half-life was 8.7 +/- 6.7 days. Patient weight, age, sex, ethnicity, history of alcoholism, hepatitis C seropositivity; and notable postoperative bleeding had no clinically relevant influences on basiliximab disposition; however, the cumulative volume of drained ascites fluid in the first week was positively correlated with clearance. Receptor-saturating basiliximab concentrations (greater than or equal to0.1 mug/mL) were maintained for 38 +/- 16 days, and this was negatively correlated with the cumulative volume of drained ascites fluid in week 1. Patients who experienced an acute rejection episode did not clear basiliximab at a faster rate than their rejection-free peers nor did they maintain CD25-saturating concentrations for a shorter period. Conclusions: Although the standard dose regimen of 20 mg of basiliximab on days 0 and 4 after transplantation appears to be appropriate for the majority of patients with liver transplants, a supplemental dose at the end of the first week may be considered for those with substantial (>10 L) postoperative ascites fluid drainage.
引用
收藏
页码:201 / 209
页数:9
相关论文
共 13 条
[1]  
AMLOT PL, 1995, MED INTELL UNIT, P53
[2]  
BEAL S, 1991, NONMEM USERS GUIDE
[3]   Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody [J].
Kahan, BD ;
Rajagopalan, PR ;
Hall, M .
TRANSPLANTATION, 1999, 67 (02) :276-284
[4]   Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts [J].
Kovarik, J ;
Wolf, P ;
Cisterne, JM ;
Mourad, G ;
Lebranchu, Y ;
Lang, P ;
Bourbigot, B ;
Cantarovich, D ;
Girault, D ;
Gerbeau, C ;
Schmidt, AG ;
Soulillou, JP .
TRANSPLANTATION, 1997, 64 (12) :1701-1705
[5]   Disposition and immunodynamics of basiliximab in liver allograft recipients [J].
Kovarik, J ;
Breidenbach, T ;
Gerbeau, C ;
Korn, A ;
Schmidt, AG ;
Nashan, B .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) :66-72
[6]   Screening for basiliximab exposure-response relationships in renal allotransplantation [J].
Kovarik, JM ;
Moore, R ;
Wolf, P ;
Abendroth, D ;
Landsberg, D ;
Soulillou, JP ;
Gerbeau, C ;
Schmidt, AG .
CLINICAL TRANSPLANTATION, 1999, 13 (01) :32-38
[7]   Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation [J].
Kovarik, JM ;
Kahan, BD ;
Rajagopalan, PR ;
Bennett, W ;
Mulloy, LL ;
Gerbeau, C ;
Hall, ML .
TRANSPLANTATION, 1999, 68 (09) :1288-1294
[8]  
KOVARIK JM, 1998, TRANSPLANTATION, V65, pS142
[9]   Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients [J].
Nashan, B ;
Moore, R ;
Amlot, P ;
Schmidt, AG ;
Abeywickrama, K ;
Soulillou, JP .
LANCET, 1997, 350 (9086) :1193-1198
[10]   Reduction of acute renal allograft rejection by daclizumab [J].
Nashan, B ;
Light, S ;
Hardie, IR ;
Lin, A ;
Johnson, JR .
TRANSPLANTATION, 1999, 67 (01) :110-115